NSPR

InspireMD Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website inspiremd.com
Employees(FY) 55
ISIN US45779A8466

Performance

+10.69%

+6.02%

-6.38%

+14.78%

-6.05%

YTD

-5.04%

Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Advanced Technical Analysis

Technical Analysis of NSPR 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 73 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NSPR

Stock Rank

Recent News & Updates

2024-11-12 13:09
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...(Yahoo Finance)
2024-11-11 18:00
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-10 18:25
What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings(Yahoo Finance)
2024-11-08 04:30
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-03 19:00
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th(Globenewswire)
2024-10-14 19:00
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System(Globenewswire)
2024-10-07 19:28
InspireMD Advances with FDA Study Approval and Global Goals(Yahoo Finance)
2024-10-06 19:00
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System(Yahoo Finance)
2024-09-15 19:00
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System(Globenewswire)
2024-08-05 20:09
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-08-04 19:00
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment(Globenewswire)
2024-07-29 19:00
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th(Globenewswire)
2024-06-30 19:00
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million(Globenewswire)
2024-05-27 20:53
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024(Yahoo Finance)
2024-05-13 22:53
NSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-13 19:00
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-05-06 19:00
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th(Globenewswire)
2024-04-02 20:59
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference(Globenewswire)
2024-03-25 19:00
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024(Yahoo Finance)
2024-03-06 21:09
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-05 23:53
NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023(Investorplace)
2024-03-05 18:00
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update(Globenewswire)
2024-02-27 18:00
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th(Globenewswire)
2024-02-11 18:00
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System(Globenewswire)
2024-02-04 22:27
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS(Zacks)
2024-01-30 18:00
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework(Globenewswire)
2024-01-02 18:00
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America(Globenewswire)
2023-12-19 18:00
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System(Globenewswire)
2023-11-26 18:00
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions(Globenewswire)
2023-11-06 20:12
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.